Remarkable clinical trial results shared internationally - ANSTO
Peter Macallum Cancer Centre's UpFrontPSMA study shows LuPSMA therapy significantly improves outcomes for newly diagnosed prostate cancer patients, with 41% achieving undetectable PSA at 48 weeks compared to 16% with standard-of-care. The results were published in *Lancet Oncology* and presented at ESMO 2024.
Highlighted Terms
Related News
Remarkable clinical trial results shared internationally - ANSTO
Peter Macallum Cancer Centre's UpFrontPSMA study shows LuPSMA therapy significantly improves outcomes for newly diagnosed prostate cancer patients, with 41% achieving undetectable PSA at 48 weeks compared to 16% with standard-of-care. The results were published in *Lancet Oncology* and presented at ESMO 2024.